Beta Blockade in Critical Injury

Denver Health and Hospital Authority

Status and phase: Terminated; Phase 2

Conditions: Trauma

Treatments: Drug: Propranolol

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00356187

R03 DK73349 (completed)

R03DK073349 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Critically injured patients endure a period of hypermetabolism/catabolism after being resuscitated. The metabolic cost of this may be measured in loss of lean body mass, poor wound healing, susceptibility to infection and long hospital stays. While there have been some data to suggest that hypermetabolism can be ameliorated in burn patients by beta blockade, to our knowledge, a prospective trial in trauma patients has not yet been done. Our hypothesis is that nonselective beta blockade will reduce catabolism, improve glucose control, blunt loss of lean body mass, decrease infections and improve outcome in a cohort of critically injured patients.

Enrollment: 15 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• ISS>25, stable at 48 hours after injury
• Fully resuscitated
• Ventilated

Exclusion Criteria Include:

• Intracranial hypertension requiring active treatment
• Hypotension/Pressors
• Already on beta blocker for a standard indication

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

15 participants in 2 patient groups

Propranol Treatment

Experimental group

Treatment:

Drug: Propranolol

Standard of Care

No Intervention group